Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Pegloticase in Kidney Transplant Recipients with Uncontrolled Gout
NCT04087720Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegloticase in gout, sponsored by Amgen. Primary endpoint: Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6. Started Sep 2019; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT04087720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087720.